GMALL Registry and Collection of Biomaterial: Prospective Data Collection Regarding Diagnosis, Treatment and Outcome of Adult Acute Lymphoblastic Leukemia (ALL) Patients and Related Diseases Associated With a Prospective Collection of Biomaterial
This is a registry study that collects information about how adult patients with acute lymphoblastic leukemia (ALL) are diagnosed, treated, and how they respond to treatment. The study gathers data from patients receiving routine clinical care, whether or not they are enrolled in other clinical trials, to help improve understanding and treatment of ALL.
Key Objective: This registry aims to improve ALL research and quality of care by systematically collecting and analyzing data on diagnosis, treatment approaches, and patient outcomes.
Who to Consider: Adults who have been diagnosed with acute lymphoblastic leukemia or related diseases and are receiving treatment should consider participating to contribute to research that may benefit future ALL patients.
Trial Parameters
Brief Summary
The GMALL registry serves the purpose of ALL research and quality assurance. The Registry collects data about diagnostics, treatment and outcome of Adult ALL Patients in the clinical routine, whether or not the patient is treated within a clinical trial.
Eligibility Criteria
Inclusion Criteria: * Acute Lymphoblastic Leukemia (All Subtypes) if treated according to ALL protocols * Other Types of Leukemia (NK Cell Lymphoma/Leukemia, Biphenotypic Acute Leukemia) if treated according to ALL protocols * Non-Hodgkin's Lymphoma of Following Subtypes: Burkitt Lymphoma, B Cell Lymphoma, B- or T-lineage Lymphoblastic Lymphoma, Anaplastic Large Cell Lymphoma, Other NHL) if treated according to B-ALL protocols * Age minimum 18 yrs